2. Novavax (NVAX) is a biopharmaceutical company focused on developing recombinant vaccines. Virus-like particles, or VLPs, drive the company's technology platform. VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins.
Total revenue for the first quarter of 2011 surged to $834,000 from $110,000 in the year-ago quarter, primarily due to services performed under the U.S. Dept. of Health and Human Services' Biomedical Advanced Research and Development Authority contract. For 2011, the company expects to generate revenue as it performs under the BARDA contract. Net loss declined to $7.5 million, or $0.07 per share, from $10.3 million, or $0.10 per share, in the comparable quarter of 2010, on lower research and development spending to support clinical trials for its H1N1 and seasonal influenza vaccine candidates.
Cash and cash equivalents stood at $8.4 million, up 3.7% from $8.1 million at the end of December 2010. Moreover, the company had a current ratio of 2.60.
All the five analysts covering the stock recommend a buy. There are no sell ratings on the stock. On average, analysts expect an upside of 218.8% to $6.38 in value from current levels.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
